Slide 1: For personal use only
For personal use only
Slide 2: Disclaimer
DISCLAIMER The information in this presentation was prepared by EBOS Group Limited (“EBOS” or the “Group”) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and, to the extent permitted by law, no representation is made as to
Slide 3: Executing with discipline, with confidence in H2 FY26 EBITDA uplift
EXECUTING WITH DISCIPLINE, WITH CONFIDENCE IN H2 FY26 EBITDA UPLIFT For personal use only • FY26 EBITDA guidance is reaffirmed, continued strong revenue growth expected, as productivity and utilisation continue to increase1 Underlying EBITDA increased 3.2% to $300 million, consistent with guidance a
Slide 4: Growth continues with H1 FY26 EBITDA in line with guidance
GROWTH CONTINUES WITH H1 FY26 EBITDA IN LINE WITH GUIDANCE1 FY26 EBITDA guidance Revenue EBITDA NPAT $615-$635m $6,768m $303m $125m For personal use only Statutory Statutory • FY26 remains unchanged • +13.0% • 9.7% • 13.0% Refer slide 6 and 7 $300m $125m Underlying Underlying • 3.2% • (4.3%) Leverag
Slide 5: Consistent operational performance and GOR growth across the portfolio
CONSISTENT OPERATIONAL PERFORMANCE AND GOR GROWTH ACROSS THE PORTFOLIO GOR Operational highlights Key drivers of growth growth1 For personal use only Symbion & Healthcare Distribution Symbion & Healthcare Distribution • Increased GLP-1 uptake • Kemps Creek went live in October 2025 Community • Focus
Slide 6: FY26 underlying EBITDA guidance reaffirmed
FY26 UNDERLYING EBITDA GUIDANCE REAFFIRMED Guidance provided at FY25 Results / Metric H1 FY26 results / progress to date Status Annual Meeting For personal use only “Group Underlying EBITDA of $615 – 635m, Underlying EBITDA reflecting ~7% midpoint growth, slightly weighted towards H2 FY26” $300m On-
Slide 7: H2 FY26 EBITDA uplift
H2 FY26 EBITDA UPLIFT H2 FY26: FY27: EBITDA growth accelerates Growth continues • Additional DC capacity in Symbion & Healthcare Distribution For personal use only • Ongoing growth of GLP-1 and other high value medicines • Further network growth across Retail Pharmacy Brands • Continued expansion of
Slide 8: Healthcare Results
TOM ere Peer a | Healthcare Results
Slide 9: Healthcare segment delivered strong topline growth and improved productivity
Community Pharmacy Healthcare Institutional Healthcare segment Contract Logistics Animal Care HEALTHCARE SEGMENT DELIVERED STRONG TOPLINE GROWTH AND Branded & Wholesale segment IMPROVED PRODUCTIVITY Healthcare segment: Underlying results (A$m) Revenue and GOR increased 11.1% and 7.3% H1 FY26 reflect
Slide 10: Community Pharmacy delivered strong top line growth, supported by GLP-1 and high value medicines
Community Pharmacy Healthcare Institutional Healthcare segment COMMUNITY PHARMACY DELIVERED STRONG TOP LINE GROWTH, Contract Logistics Animal Care Branded & Wholesale segment SUPPORTED BY DEMAND FOR GLP-1 AND HIGH VALUE MEDICINES For personal use only Underlying results (A$m) H1 FY26 H1 FY25 Change
Slide 11: Retail Pharmacy Brands continued to grow the store network and same store revenue
Community Pharmacy Healthcare Institutional Healthcare segment RETAIL PHARMACY BRANDS CONTINUED TO GROW THE STORE Contract Logistics Animal Care Branded & Wholesale segment NETWORK AND SAME STORE REVENUE For personal use only Retail Pharmacy Brands 782 stores across the network Total TWC network sal
Slide 12: Institutional Healthcare delivered solid growth, driven by MedTech
Community Pharmacy Healthcare Institutional Healthcare segment INSTITUTIONAL HEALTHCARE DELIVERED SOLID GROWTH, Contract Logistics Animal Care Branded & Wholesale segment DRIVEN BY MEDTECH For personal use only Revenue and GOR increased by 3.4% and 5.8% respectively Underlying results (A$m) H1 FY26
Slide 13: Strong growth in Contract Logistics, underpinned by investment in DC renewal program
Community Pharmacy Healthcare Institutional Healthcare segment STRONG GROWTH IN CONTRACT LOGISTICS, UNDERPINNED BY Contract Logistics Animal Care Branded & Wholesale segment INVESTMENT IN DC RENEWAL PROGRAM For personal use only Underlying results (A$m) H1 FY26 H1 FY25 Change Contract Logistics GOR
Slide 14: Animal Care Results
For personal use only Animal Care Results
Slide 15: Branded portfolio maintained solid performance; SVS accelerating wholesale growth
Community Pharmacy Healthcare Institutional Healthcare segment BRANDED PORTFOLIO MAINTAINED SOLID PERFORMANCE; SVS Contract Logistics Animal Care Branded & Wholesale segment ACCELERATING WHOLESALE GROWTH Animal Care segment: Underlying results (A$m) Integration of recent acquisitions For personal us
Slide 16: For personal use only
For personal use only
Slide 17: Strong Group revenue growth of 13% with NPAT in line with guidance
STRONG GROUP REVENUE GROWTH OF 13% WITH NPAT IN LINE WITH GUIDANCE1 For personal use only $m, except where stated H1 FY26 H1 FY25 Var% Underlying results A. Strong revenue growth of 13.0%, across Healthcare and Animal Care, Revenue 6,768 5,991 13.0% A including contribution from acquisitions GOR 868
Slide 18: Strong liquidity, disciplined capital allocation supporting growth
STRONG LIQUIDITY, DISCIPLINED CAPITAL ALLOCATION SUPPORTING GROWTH STRATEGY For personal use only • Successful refinancing completed providing approximately $930 million of undrawn committed bank facilities and current Balance weighted average term of 3.3 years (2.9 years June 2025) sheet • Leverage
Slide 19: Strong liquidity and long-dated debt maturity profile
STRONG LIQUIDITY AND LONG-DATED DEBT MATURITY PROFILE For personal use only Net debt ($m) and Leverage ratio1 1500 2.23x 2.50x • Leverage remains within target range, with the increase related 1.94x 1.89x 1.92x 2.00x to the long-term investment in the DC renewal program 1.52x 1000 1.50x • Significan
Slide 20: Disciplined net working capital management, capex elevated during transition
DISCIPLINED NET WORKING CAPITAL MANAGEMENT, CAPEX ELEVATED DURING TRANSITION Working capital ($m) & cash conversion H1 FY26 H1 FY25 Var$ Net working capital and capex supporting revenue growth and DC renewal program For personal use only Net working capital2 Trade & other receivables 1,723 1,476 (24
Slide 21: DC renewal program nears operational completion
DC RENEWAL PROGRAM NEARS OPERATIONAL COMPLETION: UNLOCKING CAPACITY, AUTOMATION AND NETWORK EFFICIENCY • Six of eight DC renewal sites now completed, with largest and most complex site, Symbion Kemps Creek, completed in October 2025, on-time and on budget. Full network benefits expected to flow thro
Slide 22: Inorganic opportunities supporting growth
INORGANIC OPPORTUNITIES SUPPORTING GROWTH Business Next Generation Pet AlphaXRT Precision Surgical MediAdvice Origin Biologics Foods1 For personal use only Division Animal Care Medical Technology Medical Technology Retail Pharmacy Management Medical Technology Queensland based manufacturer A leading
Slide 23: Interim dividend maintained, consistent with prior year
INTERIM DIVIDEND MAINTAINED, CONSISTENT WITH PRIOR YEAR For personal use only Underlying Earnings per Share (cents) • Underlying EPS of 61.4 cents, reflecting EBITDA growth and the investment in the DC renewal program, which provides capacity and enhanced capability to support future growth 147.9 15
Slide 24: For personal use only
For personal use only
Slide 25: EBOS remains a defensive growth company focused on care, productivity and partnerships
EBOS REMAINS A DEFENSIVE GROWTH COMPANY, FOCUSED ON CARE, PRODUCTIVITY AND PARTNERSHIPS TO DRIVE STRONG SHAREHOLDER RETURNS Near-term perspectives (H2 FY26) For personal use only • FY26 EBITDA guidance is reaffirmed, reflecting a positive outlook on H2 EBITDA, as productivity and utilisation continu
Slide 26: Growth enabled through divisional strategies
GROWTH ENABLED THROUGH DIVISIONAL STRATEGIES Sector dynamics For personal use only Increased pharma Stable Government Complex Ageing population New medicines Pet ownership Pet humanisation and medical spend funding healthcare needs Divisional strategies Symbion & Healthcare Retail Pharmacy Brands Me
Slide 27: Supporting Information
Supporting Information
Slide 28: PBS expenditure continues to grow, with GOR margin reflecting 1PWA pricing structure
PBS EXPENDITURE CONTINUES TO GROW, WITH GOR MARGIN REFLECTING 1PWA1 PRICING STRUCTURE AND GROWTH OF HIGH VALUE MEDICINES Average PBS prescription price2 (A$) vs EBOS Community Pharmacy GOR margin (%) • PBS volumes have grown over time albeit flattened more recently, while PBS expenditure For persona
Slide 29: GLP-1 are now a material structural driver of PBS spend and volumes
GLP-1 ARE NOW A MATERIAL STRUCTURAL DRIVER OF PBS SPEND AND VOLUMES GLP-11 volumes (m) and proportion of total PBS volumes GLP-1s are the fastest growing component of PBS spend: For personal use only GLP-1 volumes GLP-1 % of total PBS volumes • Now ~2% of PBS medicine spend (up from ~0.8% in FY22) 3
Slide 30: Segment information
SEGMENT INFORMATION Versus H1 FY25 Versus H2 FY25 Revenue GOR Revenue GOR For personal use only $m H1 FY26 H1 FY25 Var% H1 FY26 H1 FY25 Var% H1 FY26 H2 FY25 Var% H1 FY26 H2 FY25 Var% Healthcare Community Pharmacy 3,610 3,144 14.8% 310 288 7.5% 3,610 3,312 9.0% 310 299 3.5% Institutional Healthcare 2
Slide 31: Healthcare segment EBITDA by region
HEALTHCARE SEGMENT EBITDA BY REGION H1 FY26 H1 FY25 Change Healthcare segment For personal use only Revenue 6,317 5,687 11.1% Underlying EBITDA 254 250 1.3% Margin 4.0% 4.4% (40bps) Australia Revenue 4,840 4,400 10.0% Underlying EBITDA 206 200 3.0% Margin 4.2% 4.5% (30bps) New Zealand & Southeast As
Slide 32: Reconciliation of statutory to underlying results
RECONCILIATION OF STATUTORY TO UNDERLYING RESULTS For personal use only H1 FY26 H1 FY25 $m Revenue EBITDA EBIT PBT NPAT Revenue EBITDA EBIT PBT NPAT Statutory result 6,768 303 221 163 125 5,991 276 207 156 110 M&A transaction costs - 3 3 3 3 - 5 5 5 4 Restructuring & site transition costs - 20 20 20
Slide 33: Segment EBITDA and EBIT reconciliation
SEGMENT EBITDA AND EBIT RECONCILIATION EBITDA EBIT $m H1 FY26 H1 FY25 Var % H1 FY26 H1 FY25 Var% Healthcare For personal use only Statutory 257 235 9.2% 185 173 6.6% Add M&A transaction costs 3 5 3 5 Add Restructuring & site transition costs 20 10 20 10 Net gain on acquisition related activities (26
Slide 34: Glossary of terms and measures
GLOSSARY OF TERMS AND MEASURES Except where noted, common terms and measures used in this document are based upon the following definitions: Term Definition Revenue Revenue from the sale of goods and the rendering of services For personal use only Gross Operating Revenue (GOR) Revenue less cost of s
Slide 35: For personal use only
For personal use only www.ebosgroup.com